Anzeige
Mehr »
Login
Montag, 24.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Kursrakete startet...: Jetzt einsteigen und von außergewöhnlichem Potenzial profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
21.06.24
21:51 Uhr
139,26 Euro
+0,10
+0,07 %
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
138,58139,6823.06.
138,88139,3221.06.

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SoJohnson & Johnson Aktie: Umsichtige Schuldenstrategie371Johnson & Johnson hat mit einer klugen Strategie und stabilen Wachstumsaussichten den Schuldenberg souverän im Griff. Aktuelle Bilanzdaten zeigen, dass das Unternehmen Stand Ende März 2024 eine Nettoverschuldung...
► Artikel lesen
FrJanssen, Roche lead reputation rankings among blood, breast, lung and prostate cancer patient groups16
FrJ&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease2
FrJohnson & Johnson closes acquisition of biotechnology company Proteologix5
FrJohnson & Johnson seeks FDA approval for Tremfya for Crohn's disease2
FrJ&J's subcutaneous Tremfya shows promise in phase 3 Crohn's disease study3
FrJohnson & Johnson Completes Acquisition of Proteologix, Inc.80NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company...
► Artikel lesen
FrJohnson & Johnson Seeks FDA Approval For Tremfya For Moderate To Severe Crohn's Disease330NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application or sBLA to the U.S. Food and Drug Administration seeking approval of...
► Artikel lesen
DoJ&J applies for FDA approval of Tremfya for Crohn's disease4
DoJohnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA (guselkumab) for the treatment of moderately to severely active Crohn's disease30Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction...
► Artikel lesen
DoAktien New York: Dow holt auf und an Nasdaq werden Gewinne eingestrichen1.676NEW YORK (dpa-AFX) - Verluste an der boomenden Nasdaq und Kursgewinne des Leitindex Dow Jones Industrial haben am Donnerstag das Bild an den US-Börsen geprägt. Nach dem feiertagsbedingt börsenfreien...
► Artikel lesen
DoJohnson & Johnson Faces New Lawsuit(s) Related To Its Talc Products10
DoJohnson & Johnson's Arthritis Drug Shows Potential In Crohn's Disease4
DoJ&J's subcutaneous version of Tremfya excels in Crohn's disease study4
DoMinimally Invasive Surgical Instruments Market Surges to USD 49.9 Billion by 2029: Medtronic PLC (US) and Johnson & Johnson (US) at the Forefront | MarketsandMarkets228CHICAGO, June 20, 2024 /PRNewswire/ -- The minimally invasive surgical instruments market is projected to grow from USD 31.7 Billion in 2024 to USD 49.9 Billion by 2029, achieving a compound...
► Artikel lesen
DoJ&J Phase 3 study shows subcutaneous Tremfya effective in Crohn's6
DoJohnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment4
DoJohnson & Johnson: TREMFYA Phase 3 Study Meets Primary And Secondary Endpoints228NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) reported positive topline results from the Phase 3 GRAVITI investigational study of TREMFYA subcutaneous induction therapy in adult patients...
► Artikel lesen
DoJohnson & Johnson MedTech launches digital surgical ecosystem5
DoJohnson & Johnson: TREMFYA (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction79TREMFYA® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa., June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline...
► Artikel lesen
Seite:  Weiter >>
883 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
11,2,33